Jaxon Ryan
|
 |
Vardenafil ( Levitra ) (Levitra)Vardenafil (Levitra), recently launched in Belgium by Bayer and Glaxo-SmithKline, is a new drug that potently and selectively inhibits phosphodiesterase type 5 (PDE5) in the cavernosum tissue of the ***. Population dose-response model for Tadalafil ( Cialis ) in the treatment of male erectile dysfunction.PURPOSE. online pharmacy Medication of the month. Patients were randomized to receive placebo or 2, 5, 10, or 25 mg Tadalafil ( Cialis ) , taken on demand over an 8-week period. Vardenafil ( Levitra ) is thus indicated in the treatment of patients with erectile dysfunction. Estimates of maximal improvement (Emax) in the IIEF EF domain score were 7.5, 11.4, and 16.3 points for patients with mild, moderate, and severe ED, respectively. Contra-indications (co-administration with online pharmacy drugs increasing nitric oxide) and side-effects (headache and flushing due to vasodilatation) of Vardenafil ( Levitra ) are similar to those of other PDE5 inhibitors. The dosage of Vardenafil ( Levitra ) may be reduced to 5 mg (especially in older individuals) to improve tolerance or be increased up to 20 mg (especially in the presence of hair removal organic diseases aggravating erectile dysfunction) to improve efficacy. In controlled clinical trials, Vardenafil ( Levitra ) at least doubled the rate of successful erections as compared to placebo, whatever the evaluation parameter considered and the subgroup of patients studied. Vardenafil ( Levitra ) has a more potent inhibitory activity of PDE5 in vitro than Sildenafil Citrate ( Viagra ) or Tadalafil ( Cialis ) while fioricet its pharmacokinetics in vivo is somewhat more rapid than that of the two other compounds. A fifth patient response, the IIEF EF (erectile function) domain score, was modeled as a continuous variable. Efficacy was assessed on the basis of questions 2 and 3 of the Aphrodisiomaniacal Encounter Profile (SEP) and questions 3 and 4 of the International Index of Erectile Function (IIEF) questionaires. Response muchness increased substantially between 10 and 25 mg Tadalafil ( Cialis ) doses, and the dose-response parameter estimates suggested possibly higher responses at even higher doses. The dose-response relationship for each efficacy variable was best described with an Emax model, in which maximum effect increased with ED severity at baseline. Inhibition of PDE5 blocks the hydrolysis of cyclic guanosine monophosphate (GMPc) and results in increased arterial blood flow leading to enlargement of the corpus cavernosum and resulting in erection. A total of 212 male patients with mild, moderate, or severe ED participated in a multicenter, randomized, double-blind, placebo-controlled, parallel-group study. To determine the population dose-response relationship for Tadalafil ( Cialis ) during on-demand (as-needed) administration for treatment of erectile dysfunction (ED). Population dose-response modeling of all five oucome measures indicated that efficacy in all ED severity groups in the studied population generally increased across the 2 to 25 mg Tadalafil ( Cialis ) dose range. Corresponding Tadalafil ( Cialis ) doses to attain half-maximal improvement (ED50 estimates) were 4.7 mg, 7.1 mg, and 10.1 mg.. These scores were modeled using logistic regression. It is presented as 5, 10 and 20 mg tablets and the usual dose is 10 mg to be ingested 25 to 60 minutes before sexual activity.
|